Hematological Oncology最新文献

{"title":"Prognostic value of the “dynamic” R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies","authors":"Taku Kikuchi,&nbsp;Yuki Oda,&nbsp;Ukyo Kondo,&nbsp;Nobuhiro Tsukada,&nbsp;Kodai Kunisada,&nbsp;Chiaki Matsumoto,&nbsp;Moe Nomura-Yogo,&nbsp;Kota Sato,&nbsp;Tomomi Takei,&nbsp;Mizuki Ogura,&nbsp;Yu Abe,&nbsp;Kenshi Suzuki,&nbsp;Osamu Hosoya,&nbsp;Tadao Ishida","doi":"10.1002/hon.3302","DOIUrl":"10.1002/hon.3302","url":null,"abstract":"<p>To retrospectively analyze whether the second revision of the international staging system (R2-ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti-CD38 antibody-based triplet treatments. High-risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive if detected once. R2-ISS was recalculated at the initiation of treatment and defined as “dynamic R2-ISS.\" Data from 150 patients who underwent the defined treatments were analyzed. The median progression-free survival (PFS) was 19.5 months, and the median overall survival (OS) was 36.5 months. Dynamic R2-ISS significantly stratified prognoses for both PFS and OS. The median PFS for patients with dynamic R2-ISS IV was 3.3 months, and the median OS was 11.7 months, indicating extremely poor outcomes. Although the Revised International Staging System (R-ISS) calculated at the initiation of treatment significantly stratified treatment outcomes, the patients classified as R-ISS could be further stratified by R2-ISS to provide better prognostic information. Dynamic R2-ISS showed potential as a prognostic tool in patients with MM who are treated with anti-CD38 antibody-based triplet therapies.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 5","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial","authors":"Xiaohui Suo,&nbsp;Zheng Fang,&nbsp;Dongmei Wang,&nbsp;Liyun Zhao,&nbsp;Jie Liu,&nbsp;Hong Li,&nbsp;Xiaojun Ma,&nbsp;Congcong Zhang,&nbsp;Xuemei Zhao,&nbsp;Rui Shi,&nbsp;Yan Wu,&nbsp;Zongjiu Jiao,&nbsp;Jiaojie Song,&nbsp;Ling Zhang,&nbsp;Ling Li,&nbsp;Suping Zhang,&nbsp;Xinxiao Lu,&nbsp;Linyu Yuan,&nbsp;Sifeng Gao,&nbsp;Jilei Zhang,&nbsp;Kaiqi Liu,&nbsp;Xingli Zhao,&nbsp;Guanchen Bai,&nbsp;Yingchang Mi","doi":"10.1002/hon.3296","DOIUrl":"10.1002/hon.3296","url":null,"abstract":"<p>Previous research has demonstrated that the combination of Venetoclax (Ven) and intensive chemotherapy (IC) enhances the complete response (CR) and minimal residual disease (MRD) negative rate in patients with de novo Acute Myeloid Leukemia (AML).<span>^1-5</span> Our previous study showed that Ven combined with DA (2 + 6) is a highly effective and safe induction therapy for AML patients.<span>¹</span> The objective of this data update is to further substantiate the efficacy and safety of this induction regimen.</p><p>Until 30 Nov 2023, 85 patients were enrolled in this study. Baseline characteristics of 85 patients are in Table S1. According to the ELN 2022 risk classification, 37 (43.5%), 13 (15.3%), and 35 (41.2%) patients belonged to the favorable, intermediate, and adverse groups, respectively.</p><p>After one cycle induction therapy, the overall response rate (ORR, CR + CRi + PR) was 94.1% (80/85) with a composite complete response rate (cCR, CR + CRi) of 91.8% (78/85) and 85.7% (60/70) of the patients reached cCR with MRD (−) by flow cytometry. The cCR rate was 97.3% (36/37) in patients with ELN (2022) favorable risk, 84.6% (11/13) in patients with intermediate risk, and 88.6% (31/35) in patients with adverse risk (Table 1). The adverse effects and recovery time of blood cells consistent with our previous reports. Tumor lysis syndrome was only observed in one patient, and one patient died during induction therapy.</p><p>Until 30 Jan 2024, with a median follow-up of 12 (0.5–24) months, eleven (11/84, 13.1%) patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). The estimated 12-month overall survival (OS), event-free survival (EFS) and disease-free survival (DFS) rates were 82.2%, 81.9%, 82.7%, respectively (Figure S1). According to the 2022 ELN prognostic risk classification, the estimated 12-month OS, EFS, and DFS rates were 93.5% (95% CI: 88.3%–98.6%), 93.3% (95% CI: 88.1%–98.5%), and 93.3% (95% CI: 84.3%–100%), respectively, in favorable risk group; 91.7% (95% CI: 86.6%–96.8%), 90.0% (95% CI: 84.7%–95.3%), 90.9% (95% CI: 73.8%–100%), respectively, for intermediate-risk patients; and 64.6% (95% CI: 44.4%–84.8%), 62.9% (95% CI: 41.9%–83.9%), and 64.9% (95% CI: 43.7%–86.1%), respectively for adverse-risk patients (Figure 1).</p><p>Our previous study showed that Ven combined with DA (2 + 6) is a highly effective and safe induction therapy. To further corroborate our previous results, we extended the study to continue enrolled patients and continue follow-up of earlier patients.</p><p>The updated results are shown that the ORR after one cycle of induction was 94.1% (80/85) with a cCR rate of 91.8% (78/85) and MRD (−) rate 85.7%. The rates of cCR, MRD negativity, and recovery time for neutrophils and PLT counts were consistent with our previous report. The results further substantiate the efficacy and safety of our induction regimen. In comparison to previous reports,<span>^{2, 4, 5}","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital","authors":"Caroline Le Lan,&nbsp;Aurélien Belot,&nbsp;Camille Golfier,&nbsp;Bérénice Audin,&nbsp;Pierre Sesques,&nbsp;Adeline Bernier,&nbsp;Violaine Safar,&nbsp;Emmanuelle Ferrant,&nbsp;Anne Lazareth,&nbsp;Hélène Lequeu,&nbsp;Lionel Karlin,&nbsp;Dana Ghergus,&nbsp;Alizée Maarek,&nbsp;Guillaume Aussedat,&nbsp;Maryam Idlhaj,&nbsp;Gilles Salles,&nbsp;Fanny Cherblanc,&nbsp;Emmanuel Bachy,&nbsp;Hervé Ghesquieres","doi":"10.1002/hon.3297","DOIUrl":"10.1002/hon.3297","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription patterns of venetoclax in acute myeloid leukemia","authors":"Andrealuna Ucciero,&nbsp;Giuseppe Traversa,&nbsp;Alessia Pisterna,&nbsp;Valeria Cardinali,&nbsp;Sofia Sciabolacci,&nbsp;Antonella Poloni,&nbsp;Debora Capelli,&nbsp;Gianluca Gaidano,&nbsp;Andrea Patriarca,&nbsp;Monia Lunghi","doi":"10.1002/hon.3298","DOIUrl":"10.1002/hon.3298","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation","authors":"Chunxiang Xiang,&nbsp;Limin Gao,&nbsp;Qing Tao,&nbsp;Zihang Chen,&nbsp;Sha Zhao,&nbsp;Weiping Liu","doi":"10.1002/hon.3295","DOIUrl":"10.1002/hon.3295","url":null,"abstract":"<p>The biological role of Ten-11 translocation 2 (TET2) and the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in the development of extra-nodal natural killer/T-cell lymphoma (ENKTL) remains unclear. The level of 5mC and 5hmC was detected in 112 cases of ENKTL tissue specimens by immunohistochemical (IHC) staining. Subsequently, TET2 knockdown and the overexpression cell models were constructed in ENKTL cell lines. Biochemical analyses were used to assess proliferation, apoptosis, cell cycle and monoclonal formation in cells treated or untreated with L-Ascorbic acid sodium salt (LAASS). Dot-Blots were used to detect levels of genome 5mC and 5hmC. Additionally, the ILLUMINA 850k methylation chip was used to analyze the changes of TET2 regulatory genes. RNA-Seq was used to profile differentially expressed genes regulated by TET2. The global level of 5hmC was significantly decreased, while 5mC was highly expressed in ENKTL tissue. TET2 protein expression was negatively correlated with the ratio of 5mC/5hmC (<i>p</i> &lt; 0.0001). The 5mC/5hmC status were related to the site of disease, clinical stage, PINK score and Ki-67 index, as well as the 5-year OS. TET2 knockdown prolonged the DNA synthesis period, increased the cloning ability of tumor cells, increased the level of 5mC and decreased the level of 5hmC in ENKTL cells. While overexpression of TET2 presented the opposite effect. Furthermore, treatment of ENKTL cells with LAASS significantly induced ENKTL cell apoptosis. These results suggest that TET2 plays an important role in ENKTL development via regulation of 5mC and 5hmC and may serve as a novel therapeutic target for ENKTL.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location","authors":"","doi":"10.1002/hon.3223","DOIUrl":"https://doi.org/10.1002/hon.3223","url":null,"abstract":"<p>Alderuccio, J.P., Saul, E.E., Stanchina, Polar, M.K, M., Sassi, R.H., Zhao, W., Moskowitz, C.H., Reis, I., Kuker, R.A., Lossos, I.S. (2023), Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location. Hematological Oncology, 41: 103–104. https://doi.org/10.1002/hon.3163_64</p><p>In the author byline, the middle initials of the authors are missing, and the sequence is incorrect.</p><p>The incorrect author byline is:</p><p>J. P. Alderuccio, E. Edelman Saul, M. Stanchina, R. Hennemann Sassi, W. Zhao, C. Moskowitz, I. Reis, R. Kuker, I. Lossos, M. Polar</p><p>The correct author byline should be:</p><p>J.P. Alderuccio, E. Edelman Saul, M.D. Stanchina, M.K. Polar, R. Henneman Sassi, W. Zhao, C.H. Moskowitz, I. Reis, R.A. Kuker, I.S. Lossos</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141439542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy","authors":"Danai Dima,&nbsp;Utkarsh Goel,&nbsp;Aishwarya Sannareddy,&nbsp;Nnaemeka Ibeh,&nbsp;Fauzia Ullah,&nbsp;Aimaz Afrough,&nbsp;Sandra Mazzoni,&nbsp;Ali Mehdi,&nbsp;Joslyn Rudoni,&nbsp;Shahzad Raza,&nbsp;Nicole De Simone,&nbsp;Louis Williams,&nbsp;Adeel Khan,&nbsp;Aliya Rashid,&nbsp;Mikhaila Rice,&nbsp;Kristin Ricci,&nbsp;Christy Samaras,&nbsp;Jason Valent,&nbsp;Larry D. Anderson,&nbsp;Faiz Anwer,&nbsp;Gurbakhash Kaur,&nbsp;Jack Khouri","doi":"10.1002/hon.3293","DOIUrl":"10.1002/hon.3293","url":null,"abstract":"<p>Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell-directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi-institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, <i>p</i> = 0.006), and achievement of ≥VGPR (OR 21.7 <i>p</i> &lt; 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, <i>p</i> = 0.09). With a median follow-up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, <i>p</i> &lt; 0.0001) and newly diagnosed disease (NDMM; HR 0.43, <i>p</i> = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab-based regimens had a trend for better OS (<i>p</i> = 0.15), compared to other regimens, but the difference was not significant. At the end of follow-up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab-based therapies showing promise.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3293","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience","authors":"","doi":"10.1002/hon.3291","DOIUrl":"10.1002/hon.3291","url":null,"abstract":"<p>Vittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, Luca Pezzullo, Michele Merli, Flavia Rivellini, Cristina Muzi, Barbieri Emiliano, Luigi Marcheselli, Stefano Luminari. Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience. Hematol Oncol. 2023;42(3):e3273. https://doi.org/10.1002/hon.3273.</p><p>In the article, affiliation 9 is not correct. The correct affiliation is “Hematology, Azienda Unità Sanitaria Locale - IRCCS of Reggio Emilia, Reggio Emilia, Italy”.</p><p>We apologize for this error.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3291","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal dynamics of Richter transformation in chronic lymphocytic leukemia","authors":"Hanyin Wang,&nbsp;Shulan Tian,&nbsp;Charla R. Secreto,&nbsp;Sutapa Sinha,&nbsp;Min Shi,&nbsp;Timothy Call,&nbsp;Yucai Wang,&nbsp;Sameer A. Parikh,&nbsp;Saad S. Kenderian,&nbsp;Rong He,&nbsp;Jose F. Leis,&nbsp;Daniel L. VanDyke,&nbsp;Eric W. Klee,&nbsp;Susan L. Slager,&nbsp;Esteban Braggio,&nbsp;Huihuang Yan,&nbsp;Wei Ding","doi":"10.1002/hon.3282","DOIUrl":"10.1002/hon.3282","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan","authors":"Kenji Ishitsuka,&nbsp;Tomoharu Yasukawa,&nbsp;Yukie Tsuji","doi":"10.1002/hon.3292","DOIUrl":"10.1002/hon.3292","url":null,"abstract":"<p>Mogamulizumab is a humanized antibody targeting CC chemokine receptor 4 (CCR4). This post-marketing surveillance was conducted in Japan as a regulatory requirement from 2014 to 2020 to ensure the safety and effectiveness of mogamulizumab in patients with relapsed or refractory (r/r) CCR4-positive peripheral T-cell lymphoma (PTCL) or r/r cutaneous T-cell lymphoma (CTCL). Safety and effectiveness data were collected for up to 31 weeks after treatment initiation. A total of 142 patients were registered; safety was evaluated in 136 patients. The median number of doses was 8.0 (range, 1–18). The main reasons for treatment termination were insufficient response (22.1%) and adverse events (13.2%). The frequency of any grade adverse drug reaction was 57.4%, including skin disorders (26.5%), infections and immune system disorders (16.2%), and infusion-related reactions (13.2%). Graft-versus-host disease, grade 2, developed in one of two patients who underwent allogeneic-hematopoietic stem cell transplantation after receiving mogamulizumab. Effectiveness was evaluated in 131 patients (103 with PTCL; 28 with CTCL). The best overall response rate was 45.8% (PTCL, 47.6%; CTCL, 39.3%). At week 31, the survival rate was 69.0% (95% confidence interval, 59.8%–76.5%) [PTCL, 64.4% (54.0%–73.0%); CTCL, 90.5% (67.0%–97.5%)]. Safety and effectiveness were comparable between patients &lt;70 and ≥ 70 years old and between those with relapsed and refractory disease. The safety and effectiveness of mogamulizumab for PTCL and CTCL in the real world were comparable with the data reported in previous clinical trials.</p><p>Clinical Trial Registration</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3292","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}